Premium
P2‐320: COST‐EFFECTIVENESS OF MEMANTINE EXTENDED RELEASE FOR TREATMENT OF MODERATE‐TO‐SEVERE ALZHEIMER'S DISEASE IN THE UNITED STATES
Author(s) -
SaintLaurent Thibault Catherine,
Stillman Ipek Özer,
Chen Stephanie,
Getsios Denis,
Proskorovsky Irina,
Hernandez Luis,
Dixit Shailja
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.999
Subject(s) - memantine , discontinuation , medicine , quality of life (healthcare) , placebo , cohort , quality adjusted life year , disease , cost effectiveness , dementia , alternative medicine , risk analysis (engineering) , nursing , pathology
Background: We aimed to investigate whether dementia was associated with higher overall drug costs in older people. Methods: We included 4129 individuals aged 60 years from The Swedish National Study on Aging and Care (SNAC) Kungsholmen and Nordanstig (2001-2004). A generalized linear model (GLM) was used to investigate whether dementia was associated with drug costs, after adjustment for socio-demographics, functional dependency, residential setting and comorbidities. Results: Overall drug costs for persons with and without dementia were 6147 SEK and 3810 SEK, respectively. Overall, the highest cost was seen for nervous system drugs. The cost of these drugs was more than five times higher in persons with dementia than without (3202 SEK vs 585 SEK). Cardiovascular drugs were more common among persons with dementia but to a lower cost. The adjusted GLM showed that dementia was not associated with higher overall drug costs (b1⁄41.119; ns). Conclusions: We found that the observed higher overall drug costs for persons with dementia were confounded by comorbidities and residential setting. Future studies should